Monte Rosa Therapeutics Inc - ESG Rating & Company Profile powered by AI
The webpage contains a Q&A section about Monte Rosa Therapeutics Inc. Alternative companies in the rating industry group for Monte Rosa Therapeutics Inc are displayedin the table. The Sustainability rating for Monte Rosa Therapeutics Inc indicates the company's transparency towards the United Nations Sustainable Development Goals.
Monte Rosa Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 3.2 and governance score of 4.8.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
989 | Tricida Inc | 4.1 | High |
1004 | Monte Rosa Therapeutics Inc | 4.0 | High |
1004 | Can B Corp | 4.0 | High |
1004 | CLS Holdings USA Inc | 4.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Monte Rosa Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Monte Rosa Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Monte Rosa Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Monte Rosa Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Monte Rosa Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Monte Rosa Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Monte Rosa Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.